Poltreg S.A.

Warsaw Stock Exchange PTG.WA

Poltreg S.A. Operating Cash Flow for the year ending December 31, 2023: USD -3.37 M

Poltreg S.A. Operating Cash Flow is USD -3.37 M for the year ending December 31, 2023, a -71.58% change year over year. Operating cash flow is cash generated from the company’s regular business operations.

Poltreg S.A. Operating Cash Flow for the year ending December 31, 2022 was USD -1.96 M, a -106.84% change year over year.
Poltreg S.A. Operating Cash Flow for the year ending December 31, 2021 was USD -949.20 K, a -27.16% change year over year.
Poltreg S.A. Operating Cash Flow for the year ending December 31, 2020 was USD -746.43 K, a -138.37% change year over year.
Poltreg S.A. Operating Cash Flow for the year ending December 31, 2019 was USD -313.14 K, a -12.47% change year over year.

Key data

Date	Operating Cash Flow	Net Cash Used For Investing Activities	Net Cash Used Provided By Financing Activities	Dividends Paid

Warsaw Stock Exchange: PTG.WA

Poltreg S.A.

CEO	Mr. Piotr Trzonkowsk
IPO Date	Nov. 23, 2021
Location	Poland
Headquarters	Waly Piastowskie 1 lok. 1508
Employees	25
Sector	Healthcare
Industries Biotechnology Clinical Trials Pharmaceuticals Vaccines

Description

Poltreg S.A., a biotechnology company, develops therapies for autoimmune diseases using T-regulatory cells. It engages in the research and development of therapies for the treatment of type 1 diabetes in children and in multiple sclerosis. The company is based in Gdansk, Poland.

Key trends

Past 5 years